Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001144204-19-025962
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-14 15:29:32
Reporting Period:
2019-05-10
Accepted Time:
2019-05-14 15:29:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175151 Cytosorbents Corp CTSO Surgical & Medical Instruments & Apparatus (3841) 980373793
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1409212 P. Kathleen Bloch C/o Cytosorbents Corporation
7 Deer Park Drive, Suite K
Monmouth Junction NJ 08852
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-10 3,000 $6.49 3,000 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 242,725 Direct
Common Stock 9,000 Indirect See Footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.4466 to $6.4984, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. These shares were acquired by the reporting person's husband and, as such, the reporting person may be deemed the beneficial owner of such shares.
  3. Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation, as defined in the 2014 Long-Term Incentive Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,567 RSUs granted on February 28, 2018 and unvested as of the date hereof and (b) 2,714 RSUs granted on March 4, 2019 and unvested as of the date hereof and (iii) 46,944 shares of common stock owned by the reporting person.
  4. These shares are held by the reporting person's husband in a 401(k) account and as such, the reporting person may be deemed the beneficial owner of such shares.